Monitoring and reversal strategies for new oral anticoagulants.

Abstract

Thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban, apixaban and edoxaban form a new class of non-vitamin K antagonist oral anticoagulants and have been extensively studied in patients with venous thromboembolism and atrial fibrillation. They offer anticoagulation that is as effective and at least as safe compared to warfarin without the need for routine laboratory monitoring; however, no reversal strategies are currently validated in case of a non-vitamin K antagonist oral anticoagulant-associated bleed. In emergency situations, laboratory drug measurement and well-defined management for non-vitamin K antagonist oral anticoagulant-induced hemorrhage may improve clinical outcome. In this review, the merits and limitations of the routine coagulation tests and some of the more specific laboratory assays are compared. Furthermore, prohemostatic measures are reviewed and the recommended strategies in case of bleeding are summarized. Specific reversal agents are currently under development (idarucizumab for dabigatran, andexanet alfa for Xa inhibitors, and PER977 for both Xa- and thrombin inhibitors), which will facilitate clinical management of severe bleeding and emergency surgery.

DOI: 10.1586/14779072.2015.987126
0200400201520162017
Citations per Year

178 Citations

Semantic Scholar estimates that this publication has 178 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Daelen2015MonitoringAR, title={Monitoring and reversal strategies for new oral anticoagulants.}, author={Sophie Vanden Daelen and Marijke Peetermans and Thomas Vanassche and Peter B Verhamme and Erik P Vandermeulen}, journal={Expert review of cardiovascular therapy}, year={2015}, volume={13 1}, pages={95-103} }